Dr. Neil Love
Breast Cancer Update
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.
Be sure to visit the podcast's website and support the creator: www.researchtopractice.com
Author
Dr. Neil Love
Category
Podcast website
Latest episode
Nov 9, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Localized Breast Cancer — Examining the Current Use of Genetic Testing and Related Clinical Management 12.03.2025 59:43
Dr Kevin S Hughes from the Medical University of South Carolina in Charleston and Dr Mark Robson from Memorial Sloan Kettering Cancer Center in New York discuss current BRCA1/2 genetic testing practices and the clinical management of localized breast cancer with alterations in these genes. CME information and select publications here .
5-Minute Journal Club Issue 5 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer 04.03.2025 18:31
Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here .
HER2-Low and HER2-Ultralow Breast Cancer — A Roundtable Discussion on Current and Future Management Strategies 15.02.2025 2:02:17
Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, Dr Mark D Pegram from Stanford Cancer Institute in California, and Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, summarize currently available data guiding treatment decision-making for patients with low and ultralow HER2 expression and present cases from their practices. CME information...
5-Minute Journal Club Issue 4 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer 10.02.2025 10:06
Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here
5-Minute Journal Club Issue 3 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer 31.01.2025 11:58
Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here
Metastatic Triple-Negative Breast Cancer — Oncology Q&A for Clinicians: Discussing Common Questions Posed by Patients 24.01.2025 1:00:17
Dr Lisa A Carey from UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from the University of Chicago in Illinois address commonly asked questions from patients diagnosed with metastatic triple-negative breast cancer. CME information and select publications here
Oncology Q&A for Patients with Metastatic Triple-Negative Breast Cancer 17.01.2025 1:00:59
For this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill and Dr Rita Nanda from The University of Chicago to discuss the patient experience associated with the diagnosis and treatment of metastatic triple-negative breast cancer.
Metastatic Breast Cancer — San Antonio 2024 symposium series proceedings Part 3 10.01.2025 2:01:00
Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville, Tennessee, Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, Dr Joyce O’Shaughnessy from the Sarah Cannon Research Institute in Dallas, Texas, and Dr Sara M Tolaney from the Dana-Farber Cancer Institute in Boston, M...
The Role of Endocrine-Based Therapy in the Management of Breast Cancer — San Antonio 2024 symposium series proceedings Part 2 03.01.2025 2:00:37
Dr Matthew Goetz from Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, Dr Sara Hurvitz from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, and Dr Seth Wander from Massachusetts General Hospital in Boston share t...
HER2-Low and HER2-Ultralow Breast Cancer — San Antonio 2024 symposium series proceedings Part 1 23.12.2024 1:31:29
Dr Aditya Bardia, Professor Giuseppe Curigliano, Dr Hope Rugo and Dr Antonio C Wolff share their perspectives on the management of HER2-low breast cancer and the potential role of emerging data from SABCS 2024.
5-Minute Journal Club Issue 2 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer 16.12.2024 11:59
Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.
Exploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast Cancer 05.12.2024 59:42
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood and Dr Sara M Tolaney from Dana-Farber Cancer Center in Boston discuss recent updates on available and novel treatment strategies for metastatic triple-negative breast cancer.
5-Minute Journal Club Issue 1 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer 26.11.2024 10:56
Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral selective estrogen receptor degraders for ER-positive metastatic breast cancer.
Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities 19.11.2024 56:49
Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations.
Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Breast Cancer 16.11.2024 1:03:53
Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with HR-positive breast cancer.
Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer 01.11.2024 59:29
Prof Francois-Clement Bidard from Institut Curie in Paris and Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta discuss improving the outcomes of first-line endocrine-based therapy for patients with HR-positive, HER2-negative metastatic breast cancer.
Oncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer 25.10.2024 45:46
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer.
Practical Perspectives: Optimizing Diagnosis and Treatment for Patients with Desmoid Tumors 18.10.2024 59:22
Dr Thierry Alcindor from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for desmoid tumors and review novel options for targeted therapy.
Oncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer 25.09.2024 49:55
Dr Tiffany Traina from the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York, New York, discusses optimizing the management of metastatic BRCA-negative, triple-negative breast cancer.
Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer 06.09.2024 1:02:34
Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.
Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Breast Cancer from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting 29.08.2024 1:15:59
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer following the 2024 ASCO Annual Meeting.
Oncology Today with Dr Neil Love: An interview with Professor Giuseppe Curigliano, MD, PhD — Management of Metastatic Breast Cancer 23.08.2024 46:13
Prof Giuseppe Curigliano from the European Institute of Oncology in Milano, Italy discusses current questions and controversies in the management of metastatic breast cancer.
Oncology Today with Dr Neil Love: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer 16.08.2024 54:18
Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes recent trials investigating the integration of antibody-drug conjugates for HR-positive and triple-negative metastatic breast cancer.
Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer 07.08.2024 1:15:00
Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, summarizes risk factors and targeted therapy options for patients with HR-positive metastatic breast cancer.
Oncology Today with Dr Neil Love: Optimizing the Identification of HER2-Low Breast Cancer 31.07.2024 23:49
Dr Kimberly H Allison from Stanford Cancer Institute in Stanford, California, discusses the optimal identification, pathologic reporting and treatment of HER2-low breast cancer.
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.